Safety of intravenous ferric carboxymaltose versus oral iron in patients with nondialysis-dependent CKD: An analysis of the 1-year FIND-CKD trial
Nephrology Dialysis Transplantation Sep 14, 2017
Roger SD, et al. - This study was set up to assess the safety of intravenous ferric carboxymaltose (FCM) versus oral iron in patients with nondialysis-dependent chronic kidney disease (CKD). Researchers in this study with respect to data obtained highlighted correction of iron deficiency anemia with IV FCM as safe in patients with nondialysis-dependent CKD.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty -
Paid Market Research Surveys -
Case discussions, News & Journals' summaries
